
Chinese General Practice ›› 2024, Vol. 27 ›› Issue (30): 3763-3771.DOI: 10.12114/j.issn.1007-9572.2024.0019
Special Issue: 心血管最新文章合辑
• Original Research • Previous Articles Next Articles
Received:2024-02-19
Revised:2024-04-30
Published:2024-10-20
Online:2024-07-09
Contact:
ZHONG Qiuan
通讯作者:
钟秋安
作者简介:作者贡献:
刘忠典、许琪、陈伊静、覃玲巧、陈淑萍、唐薇婷进行研究的实施、数据收集与整理;刘忠典负责进行统计学处理、结果的分析与解释及撰写论文;刘忠典、钟秋安进行论文的修订;钟秋安进行文章的构思与设计、可行性分析,负责文章的质量控制及审校。
基金资助:CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2024.0019
| 组别 | 例数 | 性别[例(%)] | 年龄( | 民族[例(%)] | 受教育程度[例(%)] | BMI ( | 腰围( | 心率[M(P25,P75),bpm] | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 男 | 女 | 汉族 | 其他民族 | 初中及以下 | 高中及以上 | |||||||
| 正常组 | 272 | 108(39.7) | 164(60.3) | 56.9±7.2 | 182(66.9) | 90(33.1) | 247(90.8) | 25(9.2) | 24.5±3.2 | 84.8±8.7 | 79.0(71.0,89.0) | |
| CAS组 | 245 | 102(41.6) | 143(58.4) | 63.9±7.1 | 158(64.5) | 87(35.5) | 225(91.8) | 20(8.2) | 23.5±3.3 | 83.4±9.3 | 80.0(72.0,88.0) | |
| 检验统计量值 | 0.198a | -11.145b | 0.237a | 0.171a | 3.544b | 1.755b | -0.780 | |||||
| P值 | 0.656 | <0.001 | 0.627 | 0.679 | <0.001 | 0.080 | 0.435 | |||||
| 组别 | SBP[M(P25,P75),mmHg] | DBP( | 吸烟史[例(%)] | 饮酒史[例(%)] | 高血压[例(%)] | 糖尿病[例(%)] | ||||||
| 从不吸烟 | 曾经吸烟 | 当前吸烟 | 从不饮酒 | 曾经饮酒 | 当前饮酒 | 否 | 是 | 否 | 是 | |||
| 正常组 | 140(130,153) | 83±12 | 196(72.1) | 32(11.8) | 44(16.1) | 135(49.6) | 44(16.2) | 93(34.2) | 112(41.2) | 160(58.8) | 230(84.6) | 42(15.4) |
| CAS组 | 147(134,162) | 82±13 | 161(65.7) | 37(15.1) | 47(19.2) | 125(51.0) | 35(14.3) | 85(34.7) | 76(31.0) | 169(69.0) | 211(86.1) | 34(13.9) |
| 检验统计量值 | -3.644 | 0.998b | 2.489a | 0.360a | 5.745a | 0.251a | ||||||
| P值 | <0.001 | 0.319 | 0.288 | 0.835 | 0.017 | 0.616 | ||||||
| 组别 | 体力活动[M(P25,P75),MET-min/w] | FPG[M(P25,P75),mmol] | TC( | HDL-C[M(P25,P75),mg/dL] | LDL-C[M(P25,P75),mg/dL] | TG[M(P25,P75),mg/dL] | 脂代谢异常[例(%)] | |||||
| 否 | 是 | |||||||||||
| 正常组 | 5 643.0(3 707.3,8 325.8) | 5.6(5.2,6.1) | 213.1±41.0 | 54.5(47.1,63.8) | 118.9(96.1,139.3) | 161.7(114.9,222.8) | 55(20.2) | 217(79.8) | ||||
| CAS组 | 5 418.0(3 360.0,9 039.0) | 5.6(5.3,6.3) | 215.2±38.2 | 56.1(48.7,69.6) | 119.9(97.1,141.9) | 145.3(98.3,194.9) | 54(22.0) | 191(78.0) | ||||
| 检验统计量值 | -0.080 | -1.097 | -0.622b | -2.243 | -0.409 | -2.528 | 0.257a | |||||
| P值 | 0.937 | 0.273 | 0.534 | 0.025 | 0.683 | 0.011 | 0.612 | |||||
| 组别 | 代谢综合征[例(%)] | 肾功能[例(%)] | CRP [M(P25,P75),mg/L] | ApoA [M(P25,P75),g/L] | ApoB ( | ApoA/ApoB [M(P25,P75)] | ||||||
| 否 | 是 | 正常 | 下降 | |||||||||
| 正常组 | 146(53.7) | 126(46.3) | 132(48.5) | 140(51.5) | 1.0(0.5,2.1) | 1.6(1.5,1.8) | 1.1±0.3 | 1.4(1.1,1.8) | ||||
| CAS组 | 143(58.4) | 102(41.6) | 80(32.7) | 165(67.4) | 1.3(0.7,2.6) | 1.7(1.5,1.9) | 1.1±0.3 | 1.5(1.2,1.9) | ||||
| 检验统计量值 | 1.151a | 13.430a | -2.878 | -1.234 | -0.148b | -0.621 | ||||||
| P值 | 0.283 | <0.001 | 0.004 | 0.217 | 0.883 | 0.535 | ||||||
| 组别 | LPA[M(P25,P75),g/L] | ALT [M(P25,P75),U/L] | AST [M(P25,P75),U/L] | AST/ALT [M(P25,P75)] | UCR [M(P25,P75),g/L] | ALB[M(M(P25,P75),mg/L] | ACR[M(P25,P75),mg/g] | |||||
| 正常组 | 126.7(63.9,244.3) | 13.0(9.4,19.0) | 24.6(21.4,30.0) | 1.9(1.4,2.5) | 1.3(0.9,1.7) | 11.7(5.2,22.7) | 8.9(4.4,17.6) | |||||
| CAS组 | 166.2(74.0,322.0) | 12.3(9.0,17.6) | 25.5(22.0,31.9) | 2.0(1.6,2.6) | 1.2(0.9,1.6) | 12.2(6.1,27.9) | 9.5(5.1,22.8) | |||||
| 检验统计量值 | -2.584 | -1.151 | -1.612 | -2.561 | -0.653 | -1.179 | -1.281 | |||||
| P值 | 0.010 | 0.250 | 0.107 | 0.010 | 0.514 | 0.239 | 0.200 | |||||
Table 1 Comparison of general information between two groups
| 组别 | 例数 | 性别[例(%)] | 年龄( | 民族[例(%)] | 受教育程度[例(%)] | BMI ( | 腰围( | 心率[M(P25,P75),bpm] | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 男 | 女 | 汉族 | 其他民族 | 初中及以下 | 高中及以上 | |||||||
| 正常组 | 272 | 108(39.7) | 164(60.3) | 56.9±7.2 | 182(66.9) | 90(33.1) | 247(90.8) | 25(9.2) | 24.5±3.2 | 84.8±8.7 | 79.0(71.0,89.0) | |
| CAS组 | 245 | 102(41.6) | 143(58.4) | 63.9±7.1 | 158(64.5) | 87(35.5) | 225(91.8) | 20(8.2) | 23.5±3.3 | 83.4±9.3 | 80.0(72.0,88.0) | |
| 检验统计量值 | 0.198a | -11.145b | 0.237a | 0.171a | 3.544b | 1.755b | -0.780 | |||||
| P值 | 0.656 | <0.001 | 0.627 | 0.679 | <0.001 | 0.080 | 0.435 | |||||
| 组别 | SBP[M(P25,P75),mmHg] | DBP( | 吸烟史[例(%)] | 饮酒史[例(%)] | 高血压[例(%)] | 糖尿病[例(%)] | ||||||
| 从不吸烟 | 曾经吸烟 | 当前吸烟 | 从不饮酒 | 曾经饮酒 | 当前饮酒 | 否 | 是 | 否 | 是 | |||
| 正常组 | 140(130,153) | 83±12 | 196(72.1) | 32(11.8) | 44(16.1) | 135(49.6) | 44(16.2) | 93(34.2) | 112(41.2) | 160(58.8) | 230(84.6) | 42(15.4) |
| CAS组 | 147(134,162) | 82±13 | 161(65.7) | 37(15.1) | 47(19.2) | 125(51.0) | 35(14.3) | 85(34.7) | 76(31.0) | 169(69.0) | 211(86.1) | 34(13.9) |
| 检验统计量值 | -3.644 | 0.998b | 2.489a | 0.360a | 5.745a | 0.251a | ||||||
| P值 | <0.001 | 0.319 | 0.288 | 0.835 | 0.017 | 0.616 | ||||||
| 组别 | 体力活动[M(P25,P75),MET-min/w] | FPG[M(P25,P75),mmol] | TC( | HDL-C[M(P25,P75),mg/dL] | LDL-C[M(P25,P75),mg/dL] | TG[M(P25,P75),mg/dL] | 脂代谢异常[例(%)] | |||||
| 否 | 是 | |||||||||||
| 正常组 | 5 643.0(3 707.3,8 325.8) | 5.6(5.2,6.1) | 213.1±41.0 | 54.5(47.1,63.8) | 118.9(96.1,139.3) | 161.7(114.9,222.8) | 55(20.2) | 217(79.8) | ||||
| CAS组 | 5 418.0(3 360.0,9 039.0) | 5.6(5.3,6.3) | 215.2±38.2 | 56.1(48.7,69.6) | 119.9(97.1,141.9) | 145.3(98.3,194.9) | 54(22.0) | 191(78.0) | ||||
| 检验统计量值 | -0.080 | -1.097 | -0.622b | -2.243 | -0.409 | -2.528 | 0.257a | |||||
| P值 | 0.937 | 0.273 | 0.534 | 0.025 | 0.683 | 0.011 | 0.612 | |||||
| 组别 | 代谢综合征[例(%)] | 肾功能[例(%)] | CRP [M(P25,P75),mg/L] | ApoA [M(P25,P75),g/L] | ApoB ( | ApoA/ApoB [M(P25,P75)] | ||||||
| 否 | 是 | 正常 | 下降 | |||||||||
| 正常组 | 146(53.7) | 126(46.3) | 132(48.5) | 140(51.5) | 1.0(0.5,2.1) | 1.6(1.5,1.8) | 1.1±0.3 | 1.4(1.1,1.8) | ||||
| CAS组 | 143(58.4) | 102(41.6) | 80(32.7) | 165(67.4) | 1.3(0.7,2.6) | 1.7(1.5,1.9) | 1.1±0.3 | 1.5(1.2,1.9) | ||||
| 检验统计量值 | 1.151a | 13.430a | -2.878 | -1.234 | -0.148b | -0.621 | ||||||
| P值 | 0.283 | <0.001 | 0.004 | 0.217 | 0.883 | 0.535 | ||||||
| 组别 | LPA[M(P25,P75),g/L] | ALT [M(P25,P75),U/L] | AST [M(P25,P75),U/L] | AST/ALT [M(P25,P75)] | UCR [M(P25,P75),g/L] | ALB[M(M(P25,P75),mg/L] | ACR[M(P25,P75),mg/g] | |||||
| 正常组 | 126.7(63.9,244.3) | 13.0(9.4,19.0) | 24.6(21.4,30.0) | 1.9(1.4,2.5) | 1.3(0.9,1.7) | 11.7(5.2,22.7) | 8.9(4.4,17.6) | |||||
| CAS组 | 166.2(74.0,322.0) | 12.3(9.0,17.6) | 25.5(22.0,31.9) | 2.0(1.6,2.6) | 1.2(0.9,1.6) | 12.2(6.1,27.9) | 9.5(5.1,22.8) | |||||
| 检验统计量值 | -2.584 | -1.151 | -1.612 | -2.561 | -0.653 | -1.179 | -1.281 | |||||
| P值 | 0.010 | 0.250 | 0.107 | 0.010 | 0.514 | 0.239 | 0.200 | |||||
| 变量 | 赋值 |
|---|---|
| CAS | 否=0,是=1 |
| 性别 | 男性=1,女性=2 |
| 民族 | 汉族=1,其他民族=2 |
| 受教育程度 | 初中及以下=1,高中及以上=2 |
| 吸烟史 | 从不吸烟=1,曾经吸烟=2,当前吸烟=3 |
| 饮酒史 | 从不饮酒=1,曾经饮酒=2,当前饮酒=3 |
| 高血压 | 否=0,是=1 |
| 糖尿病 | 否=0,是=1 |
| 代谢综合征 | 否=0,是=1 |
| 脂代谢异常 | 否=0,是=1 |
| 肾功能 | 正常=1,下降=2 |
| 高血压一级亲属家族史 | 否=0,是=1 |
| 冠心病一级亲属家族史 | 否=0,是=1 |
| 糖尿病一级亲属家族史 | 否=0,是=1 |
Table 2 Lasso regression candidate variable assignment table
| 变量 | 赋值 |
|---|---|
| CAS | 否=0,是=1 |
| 性别 | 男性=1,女性=2 |
| 民族 | 汉族=1,其他民族=2 |
| 受教育程度 | 初中及以下=1,高中及以上=2 |
| 吸烟史 | 从不吸烟=1,曾经吸烟=2,当前吸烟=3 |
| 饮酒史 | 从不饮酒=1,曾经饮酒=2,当前饮酒=3 |
| 高血压 | 否=0,是=1 |
| 糖尿病 | 否=0,是=1 |
| 代谢综合征 | 否=0,是=1 |
| 脂代谢异常 | 否=0,是=1 |
| 肾功能 | 正常=1,下降=2 |
| 高血压一级亲属家族史 | 否=0,是=1 |
| 冠心病一级亲属家族史 | 否=0,是=1 |
| 糖尿病一级亲属家族史 | 否=0,是=1 |
| 变量 | 系数 | λmin |
|---|---|---|
| 年龄 | 0.026 33 | 0.019 59 |
| BMI | -0.001 48 | |
| SBP | 0.002 48 | |
| 吸烟 | 0.078 77 | |
| 饮酒 | 0.003 89 | |
| 高血压 | 0.000 02 | |
| TC | 0.000 50 | |
| HDL-C | 0.000 13 | |
| CRP | 0.001 84 | |
| FPG | 0.001 27 | |
| ApoB | 0.019 14 | |
| LPA | 0.000 16 | |
| AST | 0.000 79 | |
| AST/ALT | 0.004 44 | |
| ACR | 0.000 13 |
Table 3 Coefficients and λmin values of Lasso regression
| 变量 | 系数 | λmin |
|---|---|---|
| 年龄 | 0.026 33 | 0.019 59 |
| BMI | -0.001 48 | |
| SBP | 0.002 48 | |
| 吸烟 | 0.078 77 | |
| 饮酒 | 0.003 89 | |
| 高血压 | 0.000 02 | |
| TC | 0.000 50 | |
| HDL-C | 0.000 13 | |
| CRP | 0.001 84 | |
| FPG | 0.001 27 | |
| ApoB | 0.019 14 | |
| LPA | 0.000 16 | |
| AST | 0.000 79 | |
| AST/ALT | 0.004 44 | |
| ACR | 0.000 13 |
| 模型 | 灵敏度 | 特异度 | 准确度 | F1值 | AUC |
|---|---|---|---|---|---|
| Logistic回归 | 0.693 9 | 0.800 0 | 0.750 0 | 0.723 4 | 0.836 7 |
| RF | 0.755 1 | 0.781 8 | 0.769 2 | 0.755 1 | 0.830 1 |
| SVM | 0.714 3 | 0.818 2 | 0.769 2 | 0.744 7 | 0.841 9 |
| XGBoost | 0.734 7 | 0.818 2 | 0.778 8 | 0.757 9 | 0.833 0 |
| GBDT | 0.755 1 | 0.836 4 | 0.798 1 | 0.778 9 | 0.834 9 |
Table 4 Discriminative performance of each model on the validation set
| 模型 | 灵敏度 | 特异度 | 准确度 | F1值 | AUC |
|---|---|---|---|---|---|
| Logistic回归 | 0.693 9 | 0.800 0 | 0.750 0 | 0.723 4 | 0.836 7 |
| RF | 0.755 1 | 0.781 8 | 0.769 2 | 0.755 1 | 0.830 1 |
| SVM | 0.714 3 | 0.818 2 | 0.769 2 | 0.744 7 | 0.841 9 |
| XGBoost | 0.734 7 | 0.818 2 | 0.778 8 | 0.757 9 | 0.833 0 |
| GBDT | 0.755 1 | 0.836 4 | 0.798 1 | 0.778 9 | 0.834 9 |
| [1] |
胡盛寿,王增武. 《中国心血管健康与疾病报告2022》概述[J]. 中国心血管病研究,2023,21(7):577-600.
|
| [2] |
|
| [3] |
|
| [4] |
尤莉莉,陈新月,杨凌鹤,等. 国家基本公共卫生服务项目十年评价(2009—2019年)系列报告(三)——国家基本公共卫生服务项目实施十年:挑战与建议[J]. 中国全科医学,2022,25(26):3221-3231. DOI:10.12114/j.issn.1007-9572.2022.0406.
|
| [5] |
|
| [6] |
易艳珊,农青娇,毛宝玉,等. 基于弗明翰风险评分与血管内皮功能分类的心血管疾病危险因素研究[J]. 中国全科医学,2018,21(16):1959-1964. DOI:10.3969/j.issn.1007-9572.2018.16.011.
|
| [7] |
|
| [8] |
樊萌语,吕筠,何平平. 国际体力活动问卷中体力活动水平的计算方法[J]. 中华流行病学杂志,2014,35(8):961-964. DOI:10.3760/cma.j.issn.0254-6450.2014.08.019.
|
| [9] |
|
| [10] |
|
| [11] |
陈润霖,何土凤,陶俐均,等. 心血管危险因素对颈动脉内中膜进展的影响研究[J]. 中国全科医学,2023,26(14):1709-1715. DOI:10.12114/j.issn.1007-9572.2022.0750.
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
戴烨. 基于《中国高血压防治指南(2018修订版)》对某院门诊降压药应用情况的调查[J]. 中国社区医师,2022,38(12):11-13.
|
| [17] |
《中国老年型糖尿病防治临床指南》编写组. 中国老年2型糖尿病防治临床指南(2022年版)[J]. 中国糖尿病杂志,2022,30(1):2-51. DOI:10.3969/j.issn.1006-6187.2022.01.002.
|
| [18] |
EXPERT PANEL ON DETECTION E. Executive summary of the third report of the national cholesterol education program(NCEP)expert panel on detection,evaluation,and treatment of high blood cholesterol in adults(adult treatment panelⅢ)[J]. JAMA,2001,285(19):2486-2497. DOI:10.1001/jama.285.19.2486.
|
| [19] |
诸骏仁,高润霖,赵水平,等. 中国成人血脂异常防治指南(2016年修订版)[J]. 中国循环杂志,2016,31(10):937-953.
|
| [20] |
金文胜,潘长玉. 国际糖尿病联盟关于代谢综合征定义的全球共识[J]. 中华内分泌代谢杂志,2005,21(4):附录4b-1-附录4b-2. DOI:10.3760/j.issn:1000-6699.2005.04.054.
|
| [21] |
|
| [22] |
|
| [23] |
龚军,钟小钢,谈军涛,等. "网格搜索+XGBoost"算法建立儿童脓毒性休克预测模型[J]. 解放军医学杂志,2020,45(12):1270-1276.
|
| [24] | |
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
张萍,郭秀丽,张鹏华. 颈动脉粥样硬化与血管危险因素的相关性[J]. 中国老年学杂志,2017,37(5):1132-1134. DOI:10.3969/j.issn.1005-9202.2017.05.041.
|
| [31] |
唐焱,周宏,罗光华,等. 缺血性脑卒中患者CAS斑块超声、CT血管造影及临床相关危险因素分析[J]. 中国动脉硬化杂志,2016,24(4):391-395.
|
| [32] |
高素颖,颜应琳,于凯,等. 急性缺血性脑卒中颈动脉粥样硬化的危险因素研究[J]. 中国全科医学,2021,24(3):327-332. DOI:10.12114/j.issn.1007-9572.2020.00.401.
|
| [33] |
|
| [34] |
|
| [35] |
孔祥锋,王萍,陈明. 脂蛋白(a)与脑梗死患者颈动脉粥样硬化、纤维蛋白原、D-二聚体的关系[J]. 重庆医科大学学报,2011,36(9):1101-1102. DOI:10.13406/j.cnki.cyxb.2011.09.027.
|
| [36] |
张玮,席艳,孙慧君,等. 脂蛋白A与血栓及动脉粥样硬化的关系[J]. 中国现代医学杂志,2007,17(20):2500-2502,2505. DOI:10.3969/j.issn.1005-8982.2007.20.019.
|
| [37] |
|
| [38] |
周忠良,范小静. 西部地区基层医疗卫生服务质量及提升策略[J]. 西安交通大学学报(社会科学版),2023,43(6):188-200. DOI:10.15896/j.xjtuskxb.202306016.
|
| [39] |
| [1] | YI Shanye, YANG Rong, LIAO Xiaoyang, ZHOU Yiheng, LIU Lidi, YANG Ziyu, BAI Jiaxin, JIA Yu, ZHANG Xin. Interpretation of the 2024 Blood Pressure Measurement and Assessment of Arterial Structure and Function: an Expert Group Position Paper [J]. Chinese General Practice, 2026, 29(32): 4690-4694. |
| [2] | HU Jian, LIU Min, JIAO Zengtao, JING Wenzhan, LIANG Wannian. Research on the Risk Level Assessment of Respiratory Infectious Disease Transmission: a Case Study of COVID-19-infected Public Places [J]. Chinese General Practice, 2026, 29(32): 4738-4744. |
| [3] | GUO Junchi, ZHANG Mingyan, QIN Guangning, XU Qiang, LU Meijuan. Preliminary Application of the Novel Biomarker TANS01 in Cardiovascular Risk Assessment among Individuals with Phlegm-dampness Constitution [J]. Chinese General Practice, 2026, 29(27): 3924-3930. |
| [4] | LIU Yang, FENG Xiaojie, CHEN Jieyu, LUO Ren, ZHAO Xiaoshan, BI Jianlu. Revealing the Relationship between Lifestyle and Sub-health Based on Machine Learning: a Cross-sectional Study in Guangdong Province [J]. Chinese General Practice, 2026, 29(26): 3829-3837. |
| [5] | ZHAO Yuanyuan, LIU Pulin, DAI Juan, ZHANG Gang, ZHANG Wei, ZHANG Xiaoxia, DENG Qing, YAN Yaqiong. Association Study between Chinese Visceral Adiposity Index and Risk of All-cause and Cause-specific Mortality in the Elderly [J]. Chinese General Practice, 2026, 29(26): 3781-3787. |
| [6] | YANG Rui, LIAO Xiaoyang, HUANG Chuanying, YANG Ziyu, SHEN Can, JIA Yu, LIU Lidi, YANG Rong. Interpretation of the 2024 British and Irish Hypertension Society Position Statement: Investigation and Management of Hypertension in Young People [J]. Chinese General Practice, 2026, 29(26): 3726-3732. |
| [7] | CAO Yixin, LI Yongzhi, WEI Lingxi, ZHOU Yan, GAO Fei, YU Qi. Application Status of Traditional Computational Methods and Machine Learning in Cancer Drug Repositioning [J]. Chinese General Practice, 2026, 29(22): 3226-3232. |
| [8] | ZHANG Ji, LI Ling, ZHOU Jie, WU Yanli, JI Wei, LIU Tao. A Prospective Cohort Study on Relationship between Lipid Accumulation Product and Incidence of Metabolic Syndrome in Adults [J]. Chinese General Practice, 2026, 29(22): 3138-3145. |
| [9] | YANG Xu, FAN Jieting, SONG Hongyan, FENG Panpan, HAO Jingyu, YAO Mi. Risk Assessment and Communication Strategies for Cardiovascular Diseases in Primary Care [J]. Chinese General Practice, 2026, 29(10): 1294-1299. |
| [10] | LI Anchun, HE Zhiguang, QIU Shanjiao, CHEN Zhang, HUANG Wenjing. Opportunistic Screening Strategies and Brief Help Method for General Practice Patients with Excessive Drinking Behaviour: Insights from the RACGP Guidelines for Preventive Activities [J]. Chinese General Practice, 2026, 29(08): 974-981. |
| [11] | HUANG Wenjing, QIU Shanjiao, CHEN Zhang, LI Anchun, HE Zhiguang. Early Detection of Alzheimer's Disease in Primary Care: Insights from the RACGP Guidelines for Preventive Activities [J]. Chinese General Practice, 2026, 29(07): 823-829. |
| [12] | PEI Zhiyi, ZHANG Xiaoxin, LIN Jiayi, ZHANG Xiangyi, KANG Xiaofeng. Systematic Review of the Quality and Application of Patient Decision Aids in Cardiovascular Disease Based on IPDAS 4.0 Criteria [J]. Chinese General Practice, 2026, 29(07): 945-952. |
| [13] | ZHANG Yanjing, ZHOU Chunhua, LI Xiaodong, LIU Yan, WANG Jing, YU Jing. Study on the Clinical Value of a Risk Prediction Model for Venlafaxine Plasma Concentration Exceeding the Safety Threshold [J]. Chinese General Practice, 2026, 29(06): 777-782. |
| [14] | FAN Zhuanzhuan, LI Wenting, MA Guoliang. Relationship between the Chinese Visceral Adipose Index and Cardiovascular Disease in Postmenopausal Women: a Prospective Cohort Study [J]. Chinese General Practice, 2026, 29(02): 180-187. |
| [15] | ZHANG Shu, CHENG Yu, WU Shouling, CHEN Shuohua, WU Yuntao. The Impact of Cumulative Plasma Atherogenic Index Exposure on Incident Cardiovascular Disease in Non-Diabetic Individuals: a Cohort Study [J]. Chinese General Practice, 2025, 28(36): 4558-4565. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||